Comments

Viking Therapeutics 분석가 평가

VKTXNASDAQ

Benzinga Data가 제공하는 로고

대중과의 거래

$35.72

-0.43-1.19%

가까이에: Dec 16, 4:00 PM EST

$35.60

-0.12-0.34%

시간외: 7:11 PM EST

개요 뉴스 실적 옵션

분석가 평가

내부자 거래 매도 수량 주식 보고서

컨센서스 평점¹

Buy

최고 목표 주가¹

$138.00

최저 목표 주가¹

$19.00

컨센서스 가격 목표¹

$80.55

분석가 평가, 목표 가격, 예측

Viking Therapeutics Inc의 컨센서스 목표 주가는 $80.55이며, 22명의 애널리스트 평가를 기반으로 합니다. 최고 목표가는 9월 25, 2024에 Oppenheimer가 발표한 $138이고, 최저 목표가는 3월 29, 2023에 Roth MKM가 발표한 $19입니다. 가장 최근의 애널리스트 평가 3건은 Canaccord Genuity, Canaccord Genuity 및 JP Morgan가 11월 12, 2025, 10월 29, 2025 및 10월 24, 2025에 발표했습니다. Canaccord Genuity, Canaccord Genuity 및 JP Morgan 사이의 평균 목표 주가는 $96이며, 이 최신 평가들로부터 Viking Therapeutics Inc에 대한 169.66% upside가 시사됩니다.

분석가 추세

8월

9월

10월

11월

매수

보유

매도

강력 매도

분석가 평가

3.9

매수

강력 매수

매수

보유

매도

강력 매도

Viking Therapeutics에 대한 애널리스트 평점

					Get Alert
Nov 12, 2025	200.56%	Edward NashCanaccord Genuity 67%	106 107	Previous Buy Current Buy	Get Alert
Oct 29, 2025	197.75%	Edward NashCanaccord Genuity 67%	106	Previous Initiates Current Buy	Get Alert
Oct 24, 2025	110.67%	Hardik ParikhJP Morgan 18%	75 80	Previous Overweight Current Overweight	Get Alert
Oct 23, 2025	186.52%	Michael UlzMorgan Stanley 74%	98 102	Previous Overweight Current Overweight	Get Alert
Sep 29, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Sep 22, 2025	251.12%	Justin ZelinBTIG 39%	125 125	Previous Buy Current Buy	Get Alert
Aug 19, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Jul 24, 2025	242.7%	Ryan DeschnerRaymond James 82%	122 125	Previous Strong Buy Current Strong Buy	Get Alert
Jul 24, 2025	6.74%	David LebowitzCitigroup 68%	31 38	Previous Neutral Current Neutral	Get Alert
Jun 25, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Apr 28, 2025	192.13%	Steven SeedhouseCantor Fitzgerald 57%	104	Previous Initiates Current Overweight	Get Alert
Apr 28, 2025	110.67%	Joon LeeTruist Securities 80%	75 95	Previous Buy Current Buy	Get Alert
Apr 24, 2025	186.52%	Michael UlzMorgan Stanley 74%	102 105	Previous Overweight Current Overweight	Get Alert
Apr 24, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Apr 17, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Apr 8, 2025	-15.73%	Richard LawGoldman Sachs 31%	30	Previous Initiates Current Neutral	Get Alert
Mar 26, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Mar 11, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Feb 13, 2025	186.52%	George FarmerScotiabank 48%	102	Previous Initiates Current Sector Outperform	Get Alert
Feb 7, 2025	6.74%	David LebowitzCitigroup 68%	38	Previous Initiates Current Neutral	Get Alert
Feb 7, 2025	96.63%	Naz RahmanMaxim Group 28%	70 120	Previous Buy Current Buy	Get Alert
Feb 7, 2025	169.66%	Mayank MamtaniB. Riley Securities 76%	96 109	Previous Buy Current Buy	Get Alert
Feb 6, 2025	251.12%	Steven SeedhouseRaymond James 57%	122 125	Previous Strong Buy Current Strong Buy	Get Alert
Feb 6, 2025	99.44%	Biren AminPiper Sandler 57%	71 74	Previous Overweight Current Overweight	Get Alert
Feb 6, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Jan 17, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Jan 10, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Jan 8, 2025	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Dec 20, 2024	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Dec 18, 2024	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Dec 2, 2024	107.87%	Biren AminPiper Sandler 57%	74	Previous Initiates Current Overweight	Get Alert
Nov 27, 2024	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Nov 26, 2024	186.52%	Joseph PantginisHC Wainwright & Co. 60%	102 102	Previous Buy Current Buy	Get Alert
Nov 22, 2024	206.18%	Mayank MamtaniB. Riley Securities 76%	109	Previous Initiates Current Buy	Get Alert
Nov 5, 2024	186.52%	Joseph PantginisHC Wainwright & Co. 60%	90 102	Previous Buy Current Buy	Get Alert
Oct 24, 2024	242.7%	Steven SeedhouseRaymond James 57%	118 122	Previous Strong Buy Current Strong Buy	Get Alert
Oct 24, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Oct 9, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Sep 25, 2024	287.64%	Jay OlsonOppenheimer 68%	138 138	Previous Outperform Current Outperform	Get Alert
Sep 12, 2024	194.94%	Michael UlzMorgan Stanley 74%	105 105	Previous Overweight Current Overweight	Get Alert
Sep 11, 2024	124.72%	Hardik ParikhJP Morgan 18%	80	Previous Initiates Current Overweight	Get Alert
Jul 25, 2024	231.46%	Steven SeedhouseRaymond James 57%	116 118	Previous Strong Buy Current Strong Buy	Get Alert
Jul 25, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Jun 27, 2024	194.94%	Michael UlzMorgan Stanley 74%	105	Previous Initiates Current Overweight	Get Alert
Jun 24, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Jun 17, 2024	237.08%	Joon LeeTruist Securities 80%	120 120	Previous Buy Current Buy	Get Alert
Jun 4, 2024	—	Steven SeedhouseRaymond James 57%	—	Previous Current Strong Buy	Get Alert
Jun 4, 2024	237.08%	Naz RahmanMaxim Group 28%	120 120	Previous Buy Current Buy	Get Alert
Jun 4, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
May 16, 2024	237.08%	Joon LeeTruist Securities 80%	120 120	Previous Buy Current Buy	Get Alert
May 16, 2024	225.84%	Steven SeedhouseRaymond James 57%	115 116	Previous Outperform Current Strong Buy	Get Alert
Apr 25, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Mar 27, 2024	287.64%	Jay OlsonOppenheimer 68%	116 138	Previous Outperform Current Outperform	Get Alert
Mar 26, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Mar 26, 2024	287.64%	Jay OlsonOppenheimer 68%	116 138	Previous Outperform Current Outperform	Get Alert
Mar 26, 2024	251.12%	Justin ZelinBTIG 39%	100 125	Previous Buy Current Buy	Get Alert
Mar 15, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Mar 15, 2024	237.08%	Naz RahmanMaxim Group 28%	120 120	Previous Buy Current Buy	Get Alert
Mar 15, 2024	124.72%	Annabel SamimyStifel 71%	80	Previous Buy Current Buy	Get Alert
Mar 15, 2024	180.9%	Justin ZelinBTIG 39%	86 100	Previous Buy Current Buy	Get Alert
Mar 8, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	90 90	Previous Buy Current Buy	Get Alert
Mar 7, 2024	208.99%	Roger SongJefferies 65%	110	Previous Initiates Current Buy	Get Alert
Feb 29, 2024	237.08%	Joon LeeTruist Securities 80%	32 120	Previous Buy Current Buy	Get Alert
Feb 28, 2024	225.84%	Jay OlsonOppenheimer 68%	46 116	Previous Outperform Current Outperform	Get Alert
Feb 27, 2024	223.03%	Steven SeedhouseRaymond James 57%	37 115	Previous Outperform Current Outperform	Get Alert
Feb 27, 2024	152.81%	Joseph PantginisHC Wainwright & Co. 60%	33 90	Previous Buy Current Buy	Get Alert
Feb 14, 2024	-1.69%	Annabel SamimyStifel 71%	30 35	Previous Buy Current Buy	Get Alert
Feb 8, 2024	40.45%	Naz RahmanMaxim Group 28%	35 50	Previous Buy Current Buy	Get Alert
Dec 4, 2023	-10.11%	Joon LeeTruist Securities 80%	32	Previous Buy Current Buy	Get Alert
Oct 2, 2023	-10.11%	Joon LeeTruist Securities 80%	32	Previous Buy Current Buy	Get Alert
Aug 8, 2023	-15.73%	Annabel SamimyStifel 71%	30	Previous Current Buy	Get Alert
Jul 27, 2023	-7.3%	Joseph PantginisHC Wainwright & Co. 60%	33	Previous Buy Current Buy	Get Alert
Jun 27, 2023	-10.11%	Joon LeeTruist Securities 80%	32	Previous Buy Current Buy	Get Alert
May 31, 2023	-10.11%	Dylan DupuisRoth MKM 63%	32	Previous Current Buy	Get Alert
May 17, 2023	3.93%	Steven SeedhouseRaymond James 57%	35 37	Previous Outperform Current Outperform	Get Alert
May 16, 2023	12.36%	Jay OlsonOppenheimer 68%	35 40	Previous Outperform Current Outperform	Get Alert
May 16, 2023	-15.73%	Annabel SamimyStifel 71%	25 30	Previous Buy Current Buy	Get Alert
May 16, 2023	1.12%	Justin ZelinBTIG 39%	31 36	Previous Buy Current Buy	Get Alert
May 8, 2023	-7.3%	Joseph PantginisHC Wainwright & Co. 60%	33	Previous Current Buy	Get Alert
May 3, 2023	-32.58%	Scott HenryRoth MKM 44%	19 24	Previous Current Buy	Get Alert
Apr 27, 2023	-1.69%	Jay OlsonOppenheimer 68%	35	Previous Current Outperform	Get Alert
Apr 27, 2023	-7.3%	Joseph PantginisHC Wainwright & Co. 60%	21 33	Previous Current Buy	Get Alert
Apr 25, 2023	-1.69%	Jay OlsonOppenheimer 68%	30 35	Previous Current Outperform	Get Alert
Mar 29, 2023	-46.63%	Matt KorandaRoth MKM 58%	15 19	Previous Current Buy	Get Alert
Mar 29, 2023	-29.78%	Anthony VendettiMaxim Group 61%	15 25	Previous Current Buy	Get Alert
Mar 29, 2023	-10.11%	Joon LeeTruist Securities 80%	28 32	Previous Current Buy	Get Alert
Mar 29, 2023	-1.69%	Steven SeedhouseRaymond James 57%	12 35	Previous Current Outperform	Get Alert
Mar 29, 2023	-12.92%	Justin ZelinBTIG 39%	20 31	Previous Current Buy	Get Alert
Mar 28, 2023	-15.73%	Jay OlsonOppenheimer 68%	20 30	Previous Current Outperform	Get Alert
Mar 28, 2023	-29.78%	Annabel SamimyStifel 71%	22 25	Previous Current Buy	Get Alert
Mar 17, 2023	-38.2%	Annabel SamimyStifel 71%	22	Previous Initiates Current Buy	Get Alert
Feb 9, 2023	-66.29%	Steven SeedhouseRaymond James 57%	11 12	Previous Current Outperform	Get Alert
Feb 9, 2023	-41.01%	Joseph PantginisHC Wainwright & Co. 60%	21	Previous Current Buy	Get Alert
Dec 20, 2022	-57.87%	Naz RahmanMaxim Group 28%	10 15	Previous Current Buy	Get Alert

FAQ

Viking Therapeutics (VKTX) 주식의 목표 가격은 얼마입니까?

Viking Therapeutics (NASDAQ:VKTX)의 최신 목표 주가는 11월 12, 2025에 Canaccord Genuity에 의해 보고되었습니다. 이 애널리스트 기관은 $107.00에 대한 가격 목표를 설정했으며, 12개월 이내에 VKTX이(가) rise될 것으로 예상합니다 (가능한 200.56% upside). 지난 1년간 30개의 애널리스트 기관이 평가를 보고했습니다.

Viking Therapeutics (VKTX)에 대한 가장 최근의 애널리스트 평가는 무엇인가요?

Viking Therapeutics (NASDAQ:VKTX)에 대한 최신 애널리스트 평가는 Canaccord Genuity에 의해 제공되었으며, Viking Therapeutics은(는) buy 평가를 유지했다합니다.

Viking Therapeutics (VKTX)에 대한 마지막 업그레이드는 언제 있었나요?

Viking Therapeutics Inc에 대한 마지막 업그레이드는 5월 16, 2024에 발생했습니다. 이 때 Raymond James는 $116로 가격 목표를 올렸습니다. Raymond James는 이전에 Viking Therapeutics Inc에 대해 an outperform를 가지고 있었습니다.

Viking Therapeutics (VKTX)에 대한 마지막 다운그레이드는 언제 있었나요?

Viking Therapeutics에 대한 마지막 다운그레이드가 없습니다.

Viking Therapeutics (VKTX)에 대한 다음 애널리스트 평가는 언제 게시 또는 업데이트될 예정인가요?

애널리스트들은 주식 평가를 내리기 위해 철저한 연구를 진행합니다. 이 연구에는 공개된 재무 보고서를 검토하고, Viking Therapeutics의 경영진 및 고객과 대화하며, 실적 회의 통화를 듣는 것이 포함됩니다. 대부분의 애널리스트들은 이를 매 분기마다 수행하므로, 한 해에는 회사당 애널리스트 당 4번의 평가를 받을 수 있습니다. Viking Therapeutics에 대한 마지막 평가는 11월 12, 2025에 제출되었으므로, 다음 평가가 11월 12, 2026쯤에 제공될 것으로 예상됩니다.

애널리스트 평가 Viking Therapeutics (VKTX)가 올바른가요?

평가는 주관적이며 변할 수 있지만, 최신 Viking Therapeutics (VKTX) 평가는 유지했다로, 가격 목표는 $106.00에서 $107.00으로 조정되었습니다. 현재 Viking Therapeutics (VKTX)의 가격은 $35.60로, 이는 애널리스트의 예측 범위에서 out of입니다.

검색 애널리스트 평가 및 가격 목표 모든 주식에 대한